Rivard Report: UT Health Signs Licensing Deal With Chinese Pharmaceutical Company

June 5, 2017

UT Health San Antonio and UT Health Houston announced a landmark agreement Friday to grant exclusive global licenses for two biologic therapeutics to AlaMab Therapeutics Inc., a subsidiary of CSPC Pharmaceutical Group, in a deal that could be worth up to $114 million. Read the full report at the Rivard Report